Perez-Soler R, Lopez-Berestein G, Kasi L P, Cabanillas F, Jahns M, Glenn H, Hersh E M, Haynie T
J Nucl Med. 1985 Jul;26(7):743-9.
The distribution of 99mTc-labeled multilamellar liposomes composed of dimyristoyl phosphatidylcholine (DMPC) and dimyristoyl phosphatidylglycerol (DMPG) at a molar ratio of 7:3, administered intravenously, was studied in ten patients with Hodgkin's disease (HD). The dose of lipid was 150 mg/m2 and the mean dose of radioactivity injected per patient was 8.1 mCi (range 6.7-9.8). Whole-body imaging techniques were used, and for each organ an uptake index was calculated as the percent photographic density (PD) relative to the PD of the liver. Results were compared to those in a group of six patients with other malignancies. Increased liposome uptake in several skeletal areas was observed in one patient with HD with diffuse bone involvement and in the bone marrow of two patients with HD with bone marrow involvement. No definite liposome uptake was observed in lymph nodes involved by HD or in tumor areas of patients with other malignancies. Patients with HD had a significantly higher uptake by bone marrow (23.8% compared with 10.2% at 4 hr p = 0.02), and lungs (59.6% compared with 25.0% at 4 hr, p = 0.01) than patients with other malignancies. Among patients with HD, the uptake by bone marrow and lungs were higher in those with constitutional symptoms (bone marrow at 4 hr 31.4% compared with 16.2%, p = 0.02; lungs at 4 hr 68.8% compared with 50.4%, p = 0.19) and with liver involvement (bone marrow at 4 hr 30.8% compared with 16.8%, p = 0.03; lungs at 4 hr 73.6% compared with 45.6%, p = 0.03). These results suggest that patients with HD have a different pattern of distribution of multilamellar liposomes which may be related to a combination of nonspecific stimulation of the reticuloendothelial system and tumor uptake. It does not appear that liposomal 99mTc is capable of adequately imaging HD for clinical diagnosis.
对10例霍奇金病（HD）患者静脉注射由二肉豆蔻酰磷脂酰胆碱（DMPC）和二肉豆蔻酰磷脂酰甘油（DMPG）按摩尔比7:3组成的99mTc标记多层脂质体的分布情况进行了研究。脂质剂量为150mg/m2，每位患者注射的放射性平均剂量为8.1mCi（范围6.7 - 9.8）。采用全身成像技术，计算每个器官的摄取指数，即相对于肝脏摄影密度（PD）的摄影密度百分比。将结果与一组6例其他恶性肿瘤患者的结果进行比较。在1例有弥漫性骨受累的HD患者的几个骨骼区域以及2例有骨髓受累的HD患者的骨髓中观察到脂质体摄取增加。在HD累及的淋巴结或其他恶性肿瘤患者的肿瘤区域未观察到明确的脂质体摄取。与其他恶性肿瘤患者相比，HD患者骨髓摄取（4小时时23.8%，而其他恶性肿瘤患者为10.2%，p = 0.02）和肺部摄取（4小时时59.6%，而其他恶性肿瘤患者为25.0%，p = 0.01）明显更高。在HD患者中，有全身症状者（4小时时骨髓31.4%，而无全身症状者为16.2%，p = 0.02；4小时时肺部68.8%，而无全身症状者为50.4%，p = 0.19）和有肝脏受累者（4小时时骨髓30.8%，而无肝脏受累者为16.8%，p = 0.03；4小时时肺部73.6%，而无肝脏受累者为45.6%，p = 0.03）的骨髓和肺部摄取更高。这些结果表明，HD患者多层脂质体的分布模式不同，这可能与网状内皮系统的非特异性刺激和肿瘤摄取的综合作用有关。99mTc脂质体似乎不能充分用于HD的临床诊断成像。
